NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
ImmuneSensor Therapeutics Inc.
ImmuneSensor Therapeutics Inc.
University of Texas Southwestern Medical Center